Telomir Pharmaceuticals (TELO) said Friday it was able to stabilize both Silver(I) and the highly reactive Silver(II) in a biologically compatible form with its Telomir-1 compound.
The company said the Telomir-1 compound would help overcome hurdles in silver-based medical applications and open up new possibilities for advanced antimicrobial treatments, wound care, and infection-resistant medical coatings.
The silver-based medical treatments market is rapidly growing, with the silver wound dressings segment valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030, the company said.
Additionally, the company added that the antimicrobial coatings market, which includes silver-infused medical devices, hospital surfaces, and implants, is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031.
Telomir said it is advancing research and development to explore clinical applications of stabilized Silver(II) complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.
Shares of the company rose 5% in recent premarket trading.
Price: 4.40, Change: +0.22, Percent Change: +5.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.